Buy Lytgobi in India — Price & Availability

What is Lytgobi used for?

Lytgobi (futibatinib) is an oral, irreversible kinase inhibitor of fibroblast growth factor receptors (FGFR1, 2, 3, and 4). In cancers that carry FGFR2 alterations, this signalling pathway drives uncontrolled tumour growth; by binding FGFR and blocking its activity, Lytgobi helps slow the growth of these cancer cells.

It is approved for adults with:

• Previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer) that harbours FGFR2 gene fusions or other rearrangements.

Patient eligibility requires confirmation of an FGFR2 gene fusion or rearrangement before treatment begins. This indication was granted under accelerated approval based on overall response rate and duration of response. It is a prescription anticancer medicine and must be used under the supervision of a qualified oncologist.

Recommended dosage:
The recommended dose of Lytgobi is 20 mg (five 4 mg tablets) taken orally once daily, with or without food, at about the same time each day, continued until disease progression or unacceptable toxicity.

• Tablets are swallowed whole to ensure the full dose is delivered.
• Serum phosphate levels are monitored throughout treatment; a low-phosphate diet and phosphate-lowering therapy may be started, and the dose may be reduced, withheld, or stopped based on phosphate levels.
• Comprehensive eye examinations (including OCT of the macula) are performed before starting treatment, periodically during treatment, and if visual symptoms occur.
• If side effects occur, the dose may be reduced in steps as directed by the treating doctor.

The treating oncologist always determines the exact dose and any modifications.

Hyperphosphatemia and soft-tissue mineralisation: Lytgobi commonly raises blood phosphate levels, which can lead to calcium-phosphate deposits in tissues. Phosphate is monitored throughout treatment, and a low-phosphate diet, phosphate-lowering medicines, and dose adjustments are used to manage it. Report muscle cramps or numbness/tingling around the mouth.

• Ocular (eye) toxicity: including retinal pigment epithelial detachment (RPED), which can cause blurred vision, and dry eye. Eye exams are done before and during treatment; report any new or worsening vision changes promptly, and use lubricating eye drops as advised.
• Drug interactions: strong CYP3A/P-gp inhibitors can raise futibatinib levels and should be avoided or the dose adjusted; strong or moderate CYP3A/P-gp inducers can reduce its effectiveness and should be avoided. Futibatinib can also affect drugs that are P-gp or BCRP substrates. Share a full medication list with the treating team.
• Embryo-fetal toxicity: futibatinib can harm an unborn baby or cause loss of pregnancy; effective contraception is advised during treatment and for 1 week after the last dose (for both female patients and males with partners of reproductive potential), and breastfeeding is not recommended during and for 1 week after treatment.

Common side effects of Lytogobi

Frequently reported effects include high blood phosphate, nail changes (nail toxicity), musculoskeletal pain, constipation, diarrhoea, fatigue, dry mouth, hair loss (alopecia), mouth sores (stomatitis), abdominal pain, dry skin, joint pain, altered taste, dry eye, nausea, decreased appetite, hand-foot syndrome (palmar-plantar erythrodysesthesia), and vomiting. This is not a complete list — refer to the full prescribing information and your oncologist.

Patients in India can legally access Lytgobi through the Named Patient Program (NPP) — an import route that allows a medicine not yet registered in India to be imported in an individual patient’s name, on their physician’s prescription. The process is simple and fully documented:

• Share your request — the patient or treating doctor sends the medicine name, required quantity, and destination city.
• Eligibility & document check — we verify the prescription, diagnostic reports, and patient ID against regulatory requirements.
• Receive your quote — a transparent quotation covering medicine cost, logistics, and timeline.
• Regulatory approvals — we assist with the import permit and documentation needed for legal cross-border access.
• Import & delivery — Lytgobi is sourced and shipped under validated, temperature-controlled conditions to the patient or treating hospital.

Documents required to import Lytgobi:

• A valid prescription from a qualified oncologist
• The patient’s diagnostic reports, including FGFR2 gene fusion/rearrangement test results
• Government-issued patient ID proof
• An import permit, where applicable

Because Lytgobi is not sold on the open market in India, there is no fixed MRP. The Lytgobi cost in India depends on a few factors at the time of import:

• The number of 4 mg tablets and the pack size required per cycle, which is based on the prescribed daily dose (the standard dose is 20 mg once daily).
• The sourcing country and current ex-market price (USA, Europe, Canada, Japan, China, or Australia).
• Logistics, insurance, and any applicable customs duties or import permit costs.

Get a transparent quote: We provide a written quotation covering Lytgobi cost, logistics, and delivery timeline once a valid prescription is shared. Request your Lytgobi quote →

Lytgobi is a prescription-only medicine. Pricing is shared with patients, caregivers, and treating hospitals against a valid oncologist’s prescription, in line with applicable regulations.

Indian Pharma Network sources Lytgobi from reliable manufacturers and authorised supply channels and facilitates supply to patients, doctors, and hospitals under applicable legal provisions. Lytgobi tablets are stored at room temperature in their original packaging (patients should follow the storage conditions stated on the dispensed carton and package leaflet). All orders are dispensed and checked by registered pharmacists and dispatched after legal requirements are fulfilled.

Lytgobi can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only upon receipt of a valid doctor’s prescription and, where applicable, an import permit.

Regulatory approval status:
Lytgobi first received US FDA accelerated approval on 30 September 2022 for previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harbouring FGFR2 gene fusions or other rearrangements. It was approved in Japan in June 2023, and the European Commission granted a conditional marketing authorisation in the European Union in July 2023 for locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement after at least one prior line of systemic therapy. It is approved in several markets, including the United States, the European Union, Japan, and others. As of the current publicly available information, Lytgobi is not commercially marketed in India, which is why the Named Patient route is used.